Search
Search Results
##search.searchResults.foundPlural##
-
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4806PDF: 3959HTML: 383 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
3080PDF: 1364HTML: 2853Figure 1: 224 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9582PDF: 6338HTML: 88331Fig.1b: 300Fig.1c: 302Fig.2a: 295Fig.2b: 265Fig.4: 316Fig.2c: 280Fig.3: 281Tab.1: 342Tab.2: 314Tab.3: 305Tab.4: 345Fig1a: 296 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2518PDF: 1407HTML: 17236Bassan Fig.1: 187Bassan Fig.2: 292Bassan Fig.4: 175Fig.3: 305 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
5268PDF: 1386HTML: 1947Untitled: 237Untitled: 223 -
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4497PDF: 2057HTML: 5570Table 1: 300 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1819PDF: 1178HTML: 200 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
3112PDF: 1105HTML: 5674 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2728PDF: 1837HTML: 738 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2499PDF: 2184HTML: 259 -
POST-TRANSPLANT RELAPSE IN ACUTE LEUKEMIA: COMPARATIVE VALUE OF MRD AND CHIMERISM.
1283PDF: 675Suppl. Files: 154HTML: 552 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1665PDF: 991HTML: 2018Figure: 222Tables: 231ALL revision 1: 344response to reviewer: 234 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1935PDF: 1274HTML: 366 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3955PDF: 1742HTML: 114 -
Pathogen distribution, antimicrobial resistance, and mortality in febrile neutropenia among adults with hematological malignancies: a single-center cohort study
91PDF: 37Suppl. Files: 11Html: 25Html Suppl. Files: 6 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
3571PDF: 1202HTML: 7759cover letter paper final AML: 276 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3972PDF: 1720HTML: 889Figures . Eliassian: 325 -
OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia
1502PDF: 657Suppl. Files: 399HTML: 185 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2152PDF: 853HTML: 737Table1: patient's characteristics: 254Table 2: profile of each patient: 236 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1576PDF: 904HTML: 3151 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1945PDF: 663HTML: 374 -
-
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2878PDF: 1024HTML: 610 -
CLINICAL ASPECTS AND THERAPY OF SPORADIC BURKITT LYMPHOMA
1479PDF: 653HTML: 4203 -
ClinicaI Reversible Myelopathy in T-Cell Lymphoblastic Lymphoma Treated with Nelarabine and Radiotherapy: Report of a Case and Review of Literature of an Increasing Complication
2542PDF: 1089HTML: 1679Fig 1: 271Tab I: 263Cover Letter: 272 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1693PDF: 1111HTML: 151







